Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy
Journal of the American Chemical Society · 2025
DOI: 10.1021/jacs.5c12201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Run Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Mitochondria, Immunotherapy, Antineoplastic Agents, Drug Delivery Systems. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: State Key Laboratory of Analytical Chemistry for Life Sciences, National Key Research and Development Program of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Mitochondrial targeting of organoarsenic compounds shows potential for cancer therapy, but current delivery approaches face significant challenges such as poor tumor selectivity and systemic toxicity, leading to dose-limiting side effects and reduced therapeutic efficacy. In this study, we present a subcellular pretargeted delivery strategy designed to selectively and efficiently accumulate organoarsenic therapeutics within tumor cell mitochondria. This approach leverages P-TCO-TPP, an alkaline phosphatase (ALP)-responsive small-molecule probe containing a phosphate-caged near-infrared merocyanine fluorophore, trans-cyclooctene (TCO), and triphenylphosphonium (TPP) groups. This enables the in situ self-assembly of mitochondria-targeting nanoparticles upon ALP-mediated dephosphorylation. These mitochondria-localized nanoparticles then rapidly capture tetrazine-arsenic conjugates (Tz-As) via bioorthogonal inverse electron demand Diels-Alder (IEDDA) reaction, resulting in a >5-fold increase in mitochondrial arsenic accumulation. This, in turn, leads to mitochondrial proteins labeling, thioredoxin reductase inhibition, severe mitochondrial dysfunction, and immunogenic cell death in tumor cells. Notably, this strategy achieves strong antitumor efficacy with minimal toxicity in both subcutaneous cervical HeLa and orthotopic breast 4T1 tumor models. Furthermore, combining this strategy with anti-PD-L1 immunotherapy induces complete 4T1 tumor regression in 40% of mice, extended survival, and nearly prevents pulmonary metastasis. This subcellular pretargeted strategy offers a robust platform for precision mitochondrial drug delivery, enhancing therapeutic potential of various cytotoxic agents in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
- State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, 163 Xianlin Road, Nanjing 210023, C…
ORCID-Profile: Yingxia Li, Hong Liu, Deju Ye
Förderung
- State Key Laboratory of Analytical Chemistry for Life Sciences
- National Key Research and Development Program of China
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Joint Funds for the Innovation of Science and Technology in Fujian Province
Zitieren
APA
Wang, R., Tian, Y., Lu, X., Fang, L., Miao, Y., Fang, D., Li, Y., Liu, H., & Ye, D. (2025). Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c12201
Vancouver
Wang R, Tian Y, Lu X, Fang L, Miao Y, Fang D, et al. Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c12201
BibTeX
@article{Wang2025,
author = {Wang, Run and Tian, Yuyang and Lu, Xuliang and Fang, Leyi and Miao, Yinxing and Fang, Daqing and Li, Yingxia and Liu, Hong and Ye, Deju},
title = {Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy},
journal = {Journal of the American Chemical Society},
year = {2025},
doi = {10.1021/jacs.5c12201}
}
EUVIMED